A Phase 1 Dose-Escalation Study of LY2606368 in Combination With Ralimetinib in Patients With Advanced or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Prexasertib (Primary) ; Ralimetinib (Primary)
- Indications Colon cancer; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Eli Lilly
- 31 Aug 2017 Status changed from recruiting to completed.
- 09 Sep 2016 Status changed from not yet recruiting to recruiting.
- 10 Aug 2016 New trial record